<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994394</url>
  </required_header>
  <id_info>
    <org_study_id>156-102-00136</org_study_id>
    <secondary_id>JapicCTI-163471</secondary_id>
    <nct_id>NCT02994394</nct_id>
  </id_info>
  <brief_title>A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the bioequivalence of OPC-41061 OD tablets and OPC-41061 conventional tablets at 15
      and 30 mg in healthy adult male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the Maximum (Peak) plasma concentration of the drug (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hour Post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the Time to maximum (Peak) plasma concentration (AUC)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hour Post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy Adult Male</condition>
  <arm_group>
    <arm_group_label>OPC41061(15 mg) disintegrating tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC41061 (15 mg) orally disintegrating tablet is administered with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-41061(15 mg) disintegrating tablet without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC41061 (15 mg) orally disintegrating tablet is administered without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-41061(15 mg) conventional tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-41061 (15 mg) conventional tablet is administered with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC41061(30 mg) disintegrating tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC41061 (30 mg) orally disintegrating tablet is administered with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-41061(30 mg) disintegrating tablet without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC41061 (30 mg) orally disintegrating tablet is administered without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-41061(30 mg) conventional tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-41061 (30 mg) conventional tablet is administered with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-41061</intervention_name>
    <arm_group_label>OPC41061(15 mg) disintegrating tablet with water</arm_group_label>
    <arm_group_label>OPC-41061(15 mg) disintegrating tablet without water</arm_group_label>
    <arm_group_label>OPC-41061(15 mg) conventional tablet with water</arm_group_label>
    <arm_group_label>OPC41061(30 mg) disintegrating tablet with water</arm_group_label>
    <arm_group_label>OPC-41061(30 mg) disintegrating tablet without water</arm_group_label>
    <arm_group_label>OPC-41061(30 mg) conventional tablet with water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight of at least 50.0 kg

          -  BMI [body weight in kg / (height in m)2] of at least 17.6 kg/m2 and less than 25.0
             kg/m2

          -  Judged by the investigator or subinvestigator to be capable of providing written
             informed consent prior to the start of any trial-related procedures and capable of
             complying with the trial procedures for this study.

        Exclusion Criteria:

          -  Judged by the investigator,subinvestigator, or sponsor to have a clinically
             significant abnormality in results of the screening examination (including a notable
             deviation from the site's standard values) or a medical history that could place the
             subject at risk or affect the evaluation of drug absorption, distribution, metabolism,
             or excretion

          -  History of alcohol or drug dependence or abuse within 2 years prior to the trial

          -  History or current infection with hepatitis or acquired immunodeficiency syndrome
             (AIDS) or carrier of hepatitis B positive surface antigen (HBsAg), anti-hepatitis C
             virus (HCV), human immunodeficiency virus (HIV), or syphilis based on the results of
             the Treponema pallidum (TP) antibody test or rapid plasma reagin (RPR) test

          -  History of any severe drug allergy

          -  Positive results in alcohol screening test or urine drug screening test at time of
             screening examination or trial site admission

          -  Use of any other investigational medicinal product (IMP) within 120 days prior to
             Period 1 IMP administration

          -  Consumption of any food or beverage containing St. John's wort within 14 days prior to
             Period 1 IMP administration

          -  Consumption of any food or beverage containing grapefruit, Seville orange, or star
             fruit within 7 days prior to Period 1 IMP administration

          -  Judgment by the investigator or subinvestigator that the subject should not
             participate in the study for any other reason.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyusyu region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

